134 related articles for article (PubMed ID: 19427195)
1. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Schneider-Merck T; Borbath I; Charette N; De Saeger C; Abarca J; Leclercq I; Horsmans Y; Stärkel P
Eur J Cancer; 2009 Jul; 45(11):2050-60. PubMed ID: 19427195
[TBL] [Abstract][Full Text] [Related]
2. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
[TBL] [Abstract][Full Text] [Related]
4. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Reif S; Aeed H; Shilo Y; Reich R; Kloog Y; Kweon YO; Bruck R
J Hepatol; 2004 Aug; 41(2):235-41. PubMed ID: 15288472
[TBL] [Abstract][Full Text] [Related]
5. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
6. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Borbath I; Stärkel P
Acta Gastroenterol Belg; 2011 Mar; 74(1):34-44. PubMed ID: 21563652
[TBL] [Abstract][Full Text] [Related]
8. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of cimetidine on hepatocellular carcinomas in diethylnitrosamine-treated rats.
Furuta K; Sato S; Miyake T; Okamoto E; Ishine J; Ishihara S; Amano Y; Adachi K; Kinoshita Y
Oncol Rep; 2008 Feb; 19(2):361-8. PubMed ID: 18202782
[TBL] [Abstract][Full Text] [Related]
10. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat.
Nakaji M; Yano Y; Ninomiya T; Seo Y; Hamano K; Yoon S; Kasuga M; Teramoto T; Hayashi Y; Yokozaki H
Carcinogenesis; 2004 Mar; 25(3):389-97. PubMed ID: 14633663
[TBL] [Abstract][Full Text] [Related]
11. Ras inhibition attenuates myocardial ischemia-reperfusion injury.
Pando R; Cheporko Y; Haklai R; Maysel-Auslender S; Keren G; George J; Porat E; Sagie A; Kloog Y; Hochhauser E
Biochem Pharmacol; 2009 May; 77(10):1593-601. PubMed ID: 19426696
[TBL] [Abstract][Full Text] [Related]
12. [The expression of C-myc, N-ras mRNA and its relations to the differentiation of preneoplastic altered hepatocytes].
Lin YZ
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):97-100. PubMed ID: 8223133
[TBL] [Abstract][Full Text] [Related]
13. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
Mor A; Kloog Y; Keren G; George J
Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity.
Carmona-Cuenca I; Roncero C; Sancho P; Caja L; Fausto N; Fernández M; Fabregat I
J Hepatol; 2008 Dec; 49(6):965-76. PubMed ID: 18845355
[TBL] [Abstract][Full Text] [Related]
15. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
16. Ras-transduced diethylnitrosamine-treated hepatocytes develop into cancers of mixed phenotype in vivo.
Lin YZ; Brunt EM; Bowling W; Hafenrichter DG; Kennedy SC; Flye MW; Ponder KP
Cancer Res; 1995 Nov; 55(22):5242-50. PubMed ID: 7585583
[TBL] [Abstract][Full Text] [Related]
17. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
Borbath I; Leclercq I; Moulin P; Sempoux C; Horsmans Y
Eur J Cancer; 2007 Jul; 43(11):1755-63. PubMed ID: 17582756
[TBL] [Abstract][Full Text] [Related]
18. Alterations in enzymatic functions in hepatocytes and hepatocellular carcinomas from Ras-transduced livers resemble the effects of insulin.
Pearline RV; Lin YZ; Shen KJ; Brunt EM; Bowling WM; Hafenrichter DG; Kennedy S; Flye MW; Ponder KP
Hepatology; 1996 Oct; 24(4):838-48. PubMed ID: 8855186
[TBL] [Abstract][Full Text] [Related]
19. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y
J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats.
Bralet MP; Pichard V; Ferry N
Hepatology; 2002 Sep; 36(3):623-30. PubMed ID: 12198654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
